Skip to main content

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is an American biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare genetic diseases. The company develops small molecules, biologics, and nucleic acid therapies, commercializing products including Crysvita for X-linked hypophosphatemia, Dojolvi for fatty acid oxidation disorders, and Mepsevii for MPS VII. Main revenue drivers comprise commercial sales of proprietary rare disease therapeutics alongside partner royalty revenues and milestone payments. Ultragenyx serves rare disease medical specialists, clinical genetics centers, pediatric hospitals, and rare disease patients across North America, Europe, and Latin America. The company holds a market-leading global position in precision biopharmaceutical development for rare metabolic and genetic disorders. Headquartered in Novato, California, Ultragenyx Pharmaceutical Inc is listed on the Nasdaq Stock Market.

5 of the funds FundTelligence covers report a position in Ultragenyx Pharmaceutical.

Legal name
Ultragenyx Pharmaceutical Inc
Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding Ultragenyx Pharmaceutical

Loading...